Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report

JTO Clinical and Research Reports

Lucia A. Possamai, PhD¹  Sanjay Popat, FRCP, PhD²  Robert D. Goldin, MD²  Parvin Begum, MBChB.(Hons)³ 

[1] Reproduction, Imperial College London, London, United Kingdom;;Department of Metabolism, Digestion &Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom;

关键词: Sotorasib;    Autoimmune hepatitis;    Immune checkpoint inhibitor;    KRAS G12C;    Case report;   

DOI  :  

来源: DOAJ

【 摘 要 】

Sotorasib is a first-in-class small molecule that irreversibly inhibits KRAS G12C, locking it in an inactive state, inhibiting oncogenic signaling, and inducing a proinflammatory microenvironment. Here, we report the first case of life-threatening hepatitis in a patient with NSCLC shortly after commencing sotorasib, in which biopsy result was consistent with checkpoint inhibitor (CPI) immune-related adverse event, implicating sotorasib as being able to trigger CPI immune hepatitis. Given the large proportion of patients potentially treatable with sequential sotorasib after CPI, coupled with limited trial data, sotorasib-triggered CPI immune-related hepatitis should be considered in patients with sotorasib hepatotoxicity.

【 授权许可】

Unknown